Twist Bioscience (NASDAQ:TWST) Given New $52.00 Price Target at Barclays

Twist Bioscience (NASDAQ:TWST) had its price target lowered by Barclays from $55.00 to $52.00 in a research report sent to investors on Tuesday,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other equities analysts also recently weighed in on TWST. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. boosted their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Scotiabank lifted their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. Finally, Robert W. Baird increased their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $51.78.

Twist Bioscience Stock Performance

TWST opened at $41.89 on Tuesday. Twist Bioscience has a 52-week low of $23.07 and a 52-week high of $60.90. The stock’s 50 day moving average price is $43.93 and its 200-day moving average price is $46.15. The stock has a market capitalization of $2.49 billion, a PE ratio of -11.57 and a beta of 1.78.

Insider Buying and Selling

In related news, SVP Paula Green sold 1,057 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $43,928.92. Following the completion of the sale, the senior vice president now directly owns 121,013 shares in the company, valued at approximately $5,029,300.28. The trade was a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 14,334 shares of Twist Bioscience stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total transaction of $639,296.40. Following the transaction, the chief executive officer now owns 589,552 shares in the company, valued at $26,294,019.20. This represents a 2.37 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 98,118 shares of company stock worth $4,391,151. 3.92% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently bought and sold shares of TWST. American International Group Inc. raised its stake in Twist Bioscience by 0.8% during the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after acquiring an additional 213 shares during the period. Caprock Group LLC raised its position in shares of Twist Bioscience by 2.9% during the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after purchasing an additional 220 shares during the period. Signaturefd LLC raised its position in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the period. Arizona State Retirement System lifted its stake in shares of Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after buying an additional 308 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Twist Bioscience by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after buying an additional 312 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.